Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senores Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was ₹14.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹42.37.
During the past 12 months, the average EBIT per Share Growth Rate of Senores Pharmaceuticals was 56.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 136.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Senores Pharmaceuticals's EBIT per Share or its related term are showing as below:
NSE:SENORES'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 136.7 Med: 228.25 Max: 319.8
Current: 136.7
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Senores Pharmaceuticals was 319.80% per year. The lowest was 136.70% per year. And the median was 228.25% per year.
NSE:SENORES's 3-Year EBIT Growth Rate is ranked better than 99.38% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs NSE:SENORES: 136.70
Senores Pharmaceuticals (NSE:SENORES) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Senores Pharmaceuticals EBIT per Share Related Terms
Senores Pharmaceuticals EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹42.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senores Pharmaceuticals (NSE:SENORES) has a EBIT per Share of ₹42.37 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Senores Pharmaceuticals and its competitors. According to the industry distribution chart, Senores Pharmaceuticals ranks #5 out of 812 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Senores Pharmaceuticals' EBIT per Share too high?
Senores Pharmaceuticals' current EBIT per Share is ₹42.37. Based on the distribution chart, Senores Pharmaceuticals ranks #5 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Senores Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Senores Pharmaceuticals ranks #5 out of 812 companies for EBIT per Share. This places Senores Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.45, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Senores Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senores Pharmaceuticals's current EBIT per Share is ₹42.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current EBIT per Share of ₹42.37. The current EBIT per Share is ₹42.37. Senores Pharmaceuticals' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current EBIT per Share is ₹42.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
18GF Score
Get the complete analysis for NSE:SENORES
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SENORES has been successfully added to your 
